| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8776913 | The Breast | 2018 | 8 Pages |
Abstract
Prophylactic ACE inhibitor does not attenuate development of LV dysfunction or heart failure in patients receiving anthracycline chemotherapy ± trastuzumab. Beta-blocker attenuated reduction in LVEF and new heart failure diagnosis. However, the effect in patients only receiving anthracycline is less certain. Studies examining the effect on mortality are required.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Dorothy M. Gujral, Guy Lloyd, Sanjeev Bhattacharyya,